Joy M. Hutton leads the Grow with Google in Houston. Photo courtesy of Google

Joy M. Hutton is used to wearing multiple hats. A consultant for nonprofits and small businesses at her own firm, Joy of Consulting, and the founder of On the Go Glam, an on-demand beauty platform, Hutton recently added another hat into rotation.

In November, when Google announced it was expanding its Grow with Google Digital Coach program to Houston, Hutton was named the local leader. Now, she's hoping to help provide important business resources to entrepreneurs just like herself.

"In Houston, you have a lot of different resources that weren't available to startups before just within the past few years, and I think that's huge," Hutton says on this week's episode of the Houston Innovators Podcast. "Being more inclusive with people who need the resources who haven't traditionally had access to those resources is a big initiative. I personally am proud to be a part of that."

Hutton specifically calls out resources like MassChallenge and Founder's Institute — both of which she serves as a mentor for — as well as DivInc, gBeta, and of course the Grow with Google program. To get involved, Houston entrepreneurs can head online to learn more and keep an eye out for monthly classes online — and hopefully, in the future, in person events as well.

Just like any other entrepreneur this year, Hutton was challenged to pivot her own startup amid COVID-19 and its accompanying challenges. On the podcast, Hutton shares how the pandemic caused her to rethink the timeline on some of the features she had in mind for the company.

Originally expecting to launch at SXSW in March, On the Go Glam was focused on providing a tech platform for on-demand makeup and hair service for women. But with barber shops being closed, Hutton saw an opportunity to pivot to provide at-home services for men too.

"The pandemic was kind of a good thing, because it allowed me to take a step back and add those additional services for men," Hutton says, adding that expanding into this part of the beauty industry was always a plan, but the new need pushed her to quickly pivot to provide this service.

Hutton shares more about the new program and her observations on how Houston has evolved as a startup ecosystem in the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.